Exploring CAR T-Cell Therapy During the COVID-19 Pandemic

Exploring CAR T-Cell Therapy During the COVID-19 Pandemic

Episodes

Specialty:

All

Year:

All

EP. 1: Exploring CAR T-Cell Therapy During The COVID-19 Pandemic

July 3rd 2020

EP. 2: Exploring CAR T-Cell Therapy During the COVID-19 Pandemic: A Closer Look at Real-World Data

July 3rd 2020

EP. 3: Exploring CAR T-Cell Therapy During the COVID-19 Pandemic: Mitigation and Management of Adverse Events

July 3rd 2020

EP. 4: Exploring CAR T-Cell Therapy During COVID-19: What’s on the Horizon for CAR T-Cell Therapy

July 3rd 2020

Trending on OncLive

Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS

Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML

ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML

Dr Gangat on Phase 2 Efficacy and Safety Data for DISC-3405 in Polycythemia Vera

ELVN-001 Produces Molecular Responses in Heavily Pretreated CP-CML